CTNM
Contineum Therapeutics, Inc.Healthcare · $473M market cap
Verdict
We can't put a fair value on CTNM right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow CTNM
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 8, 2026: no open-market purchases, 1 sale worth $41K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works